CAR T-cells

2:51
CAR T-cell therapy: CRS and adverse effects
Michel Sadelain
1:04
What to expect at the upcoming EMBT-EHA CAR-T Meeting
Orla Stewart
9:35
Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells
Kanti Rai
1:07
Sequential therapy and drug resistance in CLL in the era of targeted agents
Stephan Stilgenbauer
2:11
Cellular therapies in CLL: from transplant to CAR T-cells?
Jennifer Brown
3:00
CAR T-cells for multiple myeloma: update & what’s in store for ASH 2018
Jesús Berdeja
2:42
Toxicity profile for CAR T-cells in multiple myeloma
Jesús Berdeja
11:58
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al.
11:13
CAR T-cells in lymphoma: where are we now?
David Maloney et al.
1:26
Future directions for MLL therapy
Rob Pieters
2:53
Follicular lymphoma: identifying high-risk patients
Nathan Fowler
3:07
Finding the right targets for CAR T-cell therapy in AML
Marina Konopleva
3:33
Allogeneic CD123-targeting CAR T-cell for AML: risks and potential
Marina Konopleva
3:39
CAR T-cells in CLL: the current landscape
William Wierda
1:56
Promising approaches and clinical trials in MDS
David Steensma
3:38
Anti-BCMA CAR T-cells in myeloma: what data do we have so far?
Yi Lin
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals